Related Experiment Video
Updated: Aug 14, 2025

06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
12.7K
Nonmammalian models to study Clostridioides difficile infection; a systematic review
1University of Houston College of Pharmacy, Houston, TX, 77204, USA.
Anaerobe
|January 10, 2023
Summary
Nonmammalian models offer promising alternatives to traditional mammalian studies for Clostridioides difficile infection (CDI). These models provide valuable insights into CDI pathogenesis, host immunity, and therapeutic strategies.
Area of Science:
- Microbiology
- Infectious Diseases
- Toxicology
Background:
- Clostridioides difficile is a major cause of infectious diarrhea globally, posing a significant public health threat.
- Mammalian models are standard for studying C. difficile infection (CDI) but present challenges in cost, throughput, and ethics.
- There is a growing need for alternative models to study CDI pathogenesis and develop effective treatments.
Approach:
- This review comprehensively summarizes the use of nonmammalian models for studying CDI.
- Identified studies utilized various nonmammalian systems, including the great wax worm, nematode, fruit fly, and zebrafish.
- The review analyzes the application of these models in investigating C. difficile infection, pathogenicity, colonization, host immunity, and therapeutic interventions.
Key Points:
- Nonmammalian models are effectively employed to investigate C. difficile infection dynamics.
- These alternative models facilitate research into host-pathogen interactions and immune responses during CDI.
- Studies using nonmammalian models have explored various therapeutic strategies against C. difficile.
Conclusions:
- Nonmammalian models offer viable, cost-effective, and high-throughput alternatives for CDI research.
- Each nonmammalian model presents unique strengths and weaknesses that influence their suitability for specific research questions.
- Further research utilizing these models can accelerate the development of novel CDI therapies and prevention strategies.

